JP2003527423A - 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 - Google Patents

緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物

Info

Publication number
JP2003527423A
JP2003527423A JP2001568421A JP2001568421A JP2003527423A JP 2003527423 A JP2003527423 A JP 2003527423A JP 2001568421 A JP2001568421 A JP 2001568421A JP 2001568421 A JP2001568421 A JP 2001568421A JP 2003527423 A JP2003527423 A JP 2003527423A
Authority
JP
Japan
Prior art keywords
aminopropyl
compounds
agonist activity
methyl
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001568421A
Other languages
English (en)
Japanese (ja)
Inventor
コリアー、ロバート、ジェイ、ジュニア
ディーン、トーマス、アール
ヘルバーグ、マーク、アール
Original Assignee
アルコン、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン、インコーポレイテッド filed Critical アルコン、インコーポレイテッド
Publication of JP2003527423A publication Critical patent/JP2003527423A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
JP2001568421A 2000-03-17 2001-02-20 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 Pending JP2003527423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US60/190,279 2000-03-17
PCT/US2001/005432 WO2001070223A1 (en) 2000-03-17 2001-02-20 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma

Publications (1)

Publication Number Publication Date
JP2003527423A true JP2003527423A (ja) 2003-09-16

Family

ID=22700682

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001568421A Pending JP2003527423A (ja) 2000-03-17 2001-02-20 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物
JP2001568420A Expired - Fee Related JP4789231B2 (ja) 2000-03-17 2001-02-23 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物
JP2001568428A Withdrawn JP2003527427A (ja) 2000-03-17 2001-02-23 視野損失を抑制するのに有用な５−ｈｔ活性を有する化合物
JP2010261857A Withdrawn JP2011037901A (ja) 2000-03-17 2010-11-24 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物
JP2011108785A Withdrawn JP2011153158A (ja) 2000-03-17 2011-05-13 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2001568420A Expired - Fee Related JP4789231B2 (ja) 2000-03-17 2001-02-23 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物
JP2001568428A Withdrawn JP2003527427A (ja) 2000-03-17 2001-02-23 視野損失を抑制するのに有用な５−ｈｔ活性を有する化合物
JP2010261857A Withdrawn JP2011037901A (ja) 2000-03-17 2010-11-24 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物
JP2011108785A Withdrawn JP2011153158A (ja) 2000-03-17 2011-05-13 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物

Country Status (19)

Country Link
EP (3) EP1263434A1 (US20080131398A1-20080605-C00009.png)
JP (5) JP2003527423A (US20080131398A1-20080605-C00009.png)
KR (3) KR20030016239A (US20080131398A1-20080605-C00009.png)
CN (2) CN1198605C (US20080131398A1-20080605-C00009.png)
AR (1) AR028258A1 (US20080131398A1-20080605-C00009.png)
AT (1) ATE247507T1 (US20080131398A1-20080605-C00009.png)
AU (5) AU2001238552A1 (US20080131398A1-20080605-C00009.png)
BR (3) BR0109193A (US20080131398A1-20080605-C00009.png)
CA (3) CA2400637A1 (US20080131398A1-20080605-C00009.png)
DE (1) DE60100625T2 (US20080131398A1-20080605-C00009.png)
DK (1) DK1263504T3 (US20080131398A1-20080605-C00009.png)
ES (1) ES2204848T3 (US20080131398A1-20080605-C00009.png)
HK (1) HK1051504A1 (US20080131398A1-20080605-C00009.png)
MX (3) MXPA02009071A (US20080131398A1-20080605-C00009.png)
PL (1) PL203709B1 (US20080131398A1-20080605-C00009.png)
PT (1) PT1263504E (US20080131398A1-20080605-C00009.png)
TW (1) TWI268777B (US20080131398A1-20080605-C00009.png)
WO (3) WO2001070223A1 (US20080131398A1-20080605-C00009.png)
ZA (1) ZA200206350B (US20080131398A1-20080605-C00009.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
CN100563648C (zh) * 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
AU2020228289A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
CN113784962A (zh) 2019-02-27 2021-12-10 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
WO2023118544A1 (en) * 2021-12-23 2023-06-29 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (US20080131398A1-20080605-C00009.png) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma

Also Published As

Publication number Publication date
BR0109230A (pt) 2003-06-03
DE60100625T2 (de) 2004-02-26
ZA200206350B (en) 2003-08-08
DK1263504T3 (da) 2003-12-08
CA2400639A1 (en) 2001-09-27
ES2204848T3 (es) 2004-05-01
CA2400639C (en) 2011-08-16
AU2005202600B2 (en) 2008-07-31
BR0109193A (pt) 2003-05-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
AU4531001A (en) 2001-10-03
JP2011037901A (ja) 2011-02-24
AU2001239836A1 (en) 2001-10-03
AR028258A1 (es) 2003-04-30
KR20030016239A (ko) 2003-02-26
EP1263434A1 (en) 2002-12-11
EP1263504B1 (en) 2003-08-20
WO2001070223A1 (en) 2001-09-27
JP4789231B2 (ja) 2011-10-12
EP1267878A2 (en) 2003-01-02
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
PL358306A1 (en) 2004-08-09
MXPA02009072A (es) 2003-03-12
PL203709B1 (pl) 2009-11-30
KR20020082885A (ko) 2002-10-31
WO2001070222A2 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
CN1418100A (zh) 2003-05-14
CA2399985A1 (en) 2001-09-27
JP2003527422A (ja) 2003-09-16
CN1198605C (zh) 2005-04-27
TWI268777B (en) 2006-12-21
JP2011153158A (ja) 2011-08-11
KR20030009390A (ko) 2003-01-29
HK1051504A1 (en) 2003-08-08
WO2001070230A3 (en) 2002-04-25
KR100749191B1 (ko) 2007-08-13
JP2003527427A (ja) 2003-09-16
ATE247507T1 (de) 2003-09-15
EP1263504A2 (en) 2002-12-11
WO2001070222A3 (en) 2002-07-25
CA2400637A1 (en) 2001-09-27
WO2001070230A2 (en) 2001-09-27
MXPA02009073A (es) 2003-03-12
CN1418121A (zh) 2003-05-14
DE60100625D1 (de) 2003-09-25
PT1263504E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
JP2003527423A (ja) 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物
RU2470635C2 (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
US7763619B2 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
JP2009029828A (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
JP5009468B2 (ja) 局所用水性液剤
RU2324483C2 (ru) Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
JP2001163784A (ja) 角膜または結膜用止痒剤
AU2001216071A1 (en) 5HT2 agonists for controlling IOP and treating glaucoma
JP2002506461A (ja) 網膜及び視神経の健康の最適化方法
KR20040068315A (ko) 벤조디푸란이미다졸린 및 벤조푸란이미다졸린 유도체 및녹내장 치료를 위한 이들의 용도
US20030114512A1 (en) Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
US20060211700A1 (en) (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
EP2072047A1 (en) Therapeutic agent for opthalmic disease
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
JP2003146904A (ja) 緑内障治療薬